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Three inhibitors of human immunodeficiency virus (HIV) have been isolated and purified to homogeneity from Euphorbiaceae himalaya seeds 
(Geloniunr nrrtl/iJorurn) and carnation leaves (Diantkus cnryophy/lus). These proteins, GAP 31 (Gelonium Anti-HIV Protein 31 kDa) and DAPs 
30 and 32 (dianthus anti-HIV proteins, 30 and 32 kDa), inhibit HIV-l infection and replication in a dose-dependent manner with little toxicity 
to target cells. The therapeutic indices of these compounds are in the order 104, suggesting that they may be clinically important agents in the 
treatment of AIDS. The N-terminal amino acid sequences of these proteins show little homology to those ofpreviously described anti-HIV proteins. 
The structure-function features of these HIV inhibitors, based on the 40-60 amino acid residues of N-terminal sequences, are examined, 
AIDS; Antiviral agent; Plant protein; N-terminal sequence 
1. INTRODUCTION 
We have reported previously the isolation, purifica- 
tion and characterization of two anti-HIV proteins, 
MAP 30 and TAP 29 [ 1,2]. These proteins show amino 
acid sequence homology to the ribosome-inactivating 
proteins, trichosanthin and ricin A chain [3,4]. Further 
studies indicate that MAP 30 and TAP 29 also inhibit 
in vitro eukaryotic translation, and are thus single-chain 
ribosome-inactivating proteins (SCRIPS). However, in 
contrast to trichosanthin and ricin A chain, MAP 30 
and TAP 29 exhibit little cytotoxicity to target cells. 
In this article, we report a new class of anti-I-IIV 
SCRIPS from distinct and unrelated plant species, that 
possess high antiviral potency and low toxicity to nor- 
ma1 cells in culture as well as to intact animals. In addi- 
tion, we also report the N-terminal amino acid sequen- 
ces of these anti-HIV proteins. 
2.2. Anti-HIV conlpounds: GAP 31, DAP 30 arid DAP 32 
All anti-HIV agents used in this study have been purified to homo- 
geneity. GAP 31 was purified from Euphorbiaceae himalaya seeds 
(Grloniurn nzultiflorurn). DAPs 30 and 32 were purified from carnation 
leaves (Dinrrlkrts curyopl~ylh~s). The source materials for these prepara- 
tions were supplied by American BioSciences, New York. 
2.3. Characterizn~iotrs 
The homogeneity and size of the purified anti-HIV agents were 
determined by SDS-PAGE. Protein sequencing was carried out by 
automated Edman degradation using an Applied Biosystems model 
470A protein sequencer, with on-line PTH analyzer. 
2.4. Anti-HIV and ofher crsscq~s 
Anti-HIV activity was measured by microtiter syncytium formation 
in infectious cell center assay [S], viral core protein p24 expression [6], 
and viral-associated reverse transcriptase (RT) activity [7]. 
The CEM-ss (syncytium sensitive, Leu-3 positive) cell line was used 
as the indicator cell for the microtiter syncytial-forming assay. The H9 
ccl1 line was used for p24 expression and HIV-RT activity assays, 
HIV-I virus was prepared and stocked as descri bed previously 161. Cell 
lines were cultured in RPMI-1640 medium containing 100 U/ml of 
penicillin-streptomycin and 10% heat-inactivated fetal calf serum. 
2. MATERIALS AND METHODS 
2.1 . C/rertricul.~ 
Carboxymethyl cellulose (CMS2) was a product of Whatman. Con 
A Sepharosc CL-4B was obtained from Pharmacia-LKB, ‘H-labclcd 
thymidine and leucine, alid rabbit rcticulocytc lysate transhition sys- 
tcms wcrc purcltarcd from DuPont~Ncw England Nuclear. 
The cytoloxicities of the HIV inhibitors were measured by their 
cffccts on cellular DNA and protein syntheses it. uninfected H9 cells 
[I], The toxicity to intact animals was dctcrmincc by intraperitoneal 
injection (i,p.) of these inhibitors into adult mice. 
The ribosome-innctivating activity was measured ,~y cell-free trans- 
lation of globin rnessagc in a rabbit rcticulocytc lysate system as 
described previously [I]. 
3. RESULTS 
3.1. Prqmrurion md cl~crrrlcte~i=Nriort of GAP 31, DAP 
311 utrtl BAP 32 
The anti-HIV compounds were prepared by a three- 
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Fig. 1. SDS-PAGE of GAP 3 1, DAP 30 and DAP 32. Electrophoresis 
was carried out in the presence of the reducing agent 2-mcrcaptoetha- 
no1 in 10% acrylamide at a constant voltage of 90 V for S h, until the 
Bromophenol blue tracking dye reached 1 cm from the lower edge of 
the gel, The gels were stained with silver stain. Lane 1, molecular 
weight standards (2 hug each), lanes 2, 3 and 4. GAP 31 (2 pug), DAP 
30 (2 JQ) and DAP 32 (3 ~6). 
step procedure consisting of: (a) initial extraction with 
10 mM sodium phosphate buffer, pH 9.2, containing 
0.15 M NaCl (PBS), (b) cationic chromatography on 
CM 52, and (c) affinity chromatography on Con A 
Sepharose CL-4B. 
Shelled Geloniwn tnuitzj7orurn seeds or cleaned Dim- 
thus caryopl~yllus leaves were extracted with PBS at ra- 
tios of 15 or I:2 (w/v), respectively. Extraction was 
carried out in a tissue blender for 6 min at 4”?=, The 
extract was stirred gently overnight followed by centri- 
fugation at 16 000 x g for 30 min to remove cell debris. 
The supernatant was concentrated by ammonium sul- 
fate precipitation to 90% saturation, The precipitate 
was dissolved in a minimum volume of 5 mM sodium 
phosphate, pH 6.4 (buffer A) and dialyzed exhaustively 
against he same buffer. The dialyzed sample was load- 
ed onto a column of CM 52 (1.5 x 36 cm), which was 
equilibrated with buffer A. The column was washed 
with the same buffer A until the baseline of A,,, was 
reached. The majority of the impurities were excluded 
from the column while the anti-HIV proteins were re- 
tained, They were eluted with a line,zr gradient of O-300 
mM NaCl in buffer A (15 x column volume). GAP 31 
was eluted at about 0.2-0,26 NaCl. DAP 30 and DAP 
32 were eluted at about 0.14 and 0.18 NaCl, respec- 
tively. The active fractions were pooled and concentra- 
ted by ammonium sulfate precipitation to 85% satura- 
tion. The samples were then dialyzed against buffer A 
and further purified by Con A-Sepharose CL-4B. Impu- 
rities were excluded from the column, wfrereas tfle anti- 
HIV activity was selectively bound to Con A and rc- 
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Fig. 2. The effects of GAP 31, DAP 30 and DAP 32 on HIV-I 
infection, Results given in this figure represent averages of triplicates 
from two independent experiments. Triplicate wells of indicator cells 
containing the testing drugs at each concentration without virus were 
also included for the determination of the cytotoxic and cytostatic 
activities of these HIV inhibitors. Infectious cell center (% ICC) are 
expressed in terms of V,,/ V,, where V, and V, are average numbers of 
syncytia in the drug-treated and untreated samples, respectively. 
tained. GAP 31 was eluted with 0.1 M ol-methylman- 
noside in buffer A. DAPs 30 and 32 were eluted with 
0.25 M a-methylmannoside in buffer A or by 60 mM 
sodium borate in 10 mM Tris-NC1 buffer, pH 9.4. The 
homogeneity and size of the purified material were de- 
termined by SDS-PAGE. Single bands with mol. mass 
of 31. 30 and 32 kDa were obtained for GAP 31, DAP 
30 and DAP 32, respectively (Fig. 1). Identical results 
were obtained under reducing and non-reducing condi- 
tions, indicating that these molecules are single chain 
polypeptides. 
3.2. Effects 011 HIV-1 hfectiorz 
The effects of GAP 3 1, DAP 30 and DAP 32 on 
HIV-l infection were measured by their inhibition of 
syncytium formation in infectious cell center assays, 
This assay quantitates acute cell-free HIV infection. The 
results are summarized in Fig. 2. All of the compounds 
exhibit dose-dependent inhibition of syncytium forma- 
tion with IDSOs of 0.28, 0.83, and 0,96 nM for GAP 31, 
DAP 30 and DAP 32, respectively. No cytotoxic or 
cytostatic effects were observed under the assay condi- 
tions. These results suggest hat GAP 3 1. DAP 30 and 
DAP 32 affect the initial HIV-1 infection as well as 
transmission of viral gene products through ccl1 contact 
or release of free virions. 
The effects of GAP 31, DAP 30 and DAP 32 on 
HIV-l replication were measured in a suspension cul- 
turc of H9 cells. In this assay, the expression of viral 
core protein ~24 and HIV-RT activity in HIV-infected 
H9 cells were examined at various concentrations of 
these agents The results arc shown in Fig. 3. Eacfl of 
these compounds dernonstratcs a dose-depcndcnt inhi- 
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Fig. 3. The effects of GAP 3 1, DAP 30 and DAP 32 on HIV-I replication. p24 production was determined by RIA and expressed in ng/ml. Viral-RT 
activity was determined by the incorporation of rH]dTTP into TCA-precipitable products and expressed in terms of cpm x lO”/ml. These values 
in control culture (without he addition of the inhibitor) were 2219 r&/ml and 846 x I@’ cpm/rnl, respectively, as determined in triplicates in two 
independent experiments. 
bition of HIV-l replication. The IDSUs for GAP 31, 
DAP 30 and DA19 32 were 0.23, 0.86 and 0.71 nM for 
la0 
T DNA Synthesis 
~24 expression, and 0.32,0.88 and 0.46 nM for HIV-WT 
activity. The reduction in $4 expression was not due 
Protein Synthesis 
0 0.32 3.2 32 320 0 0.32 3.2 32 320 
Concentration MWI 
Fig, 4, Cytotoxicities of GAP 31, DAP 30 and DAP 32. Cytotoxicitics were measured by cellular incorporation of “I-I-labeled thymidinc or lcucine 
into TCA-precipitablc products in pulse-labeling experiments. H9 cells were scedcd into 96well plates at 2 x lO%vell. The culture was pulsed with 
I /Ki (I Ci = 37 GBq) of [“H]thymidinc or [“H]lcucine 8h prior to harvesting at day 4, Cellular synthesis of DNA and protein wcrc dctcrmined 
by scintillation counting of the incorporation of labclcd precursors Results arc normalized to values obtained for control cultures without drug. 
Control cpm for ‘H-labeled thymicline and leucine wcrc 201 x lo3 and Cl x lo”. rcspcctivcly. Results shown arc averages of triplicates in two 
indepcnclcnt cxpcrimcnts 
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Fig. 5. Comparison of the N-terminal amino acid sequences of GAP 
31, DAP 30 and DAP 32 to the N-terminal sequences of MAP 30, 25 30 35 
trichosanthin (TRI) and ricin A chain (RIG A) residues 7-51 as repor- GAP 31 LBXbRVX~RBEBNSHBTs~~~ 
ted earlier [1,3,4]. Sequences are aligned to maximize similarities be- iHLELVLBBNADNER8PPBL 
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Fig. 6. (a) Comparison of the N-terminal sequences of DAP 30 and 
ATAYTLNLANPSASQYSXFLDQIRNNVRD 
DAP32AVKTITLNLV@PSANRY~TFLTElRDNVRX 
DAP3Cl p-, m a 
SAP-6 AVTSLTLDLVNPTAGQYSSFVDKFVDK I RN 
a 
to cytotoxic or cytostatic effects; no inhibition of DNA 
or nrotein svnthesis was detected at the dose level of the 
assay. The hecrease in HIV.RT activity is likely to be 
due to an inhibition in virion production, which is also 
evidenced by the reduced p24 expression. 
DAP 32 to that of saporin-6 (SAP-6) from Saponaria officinalis, rcsi- 
dues 25-70 [IO]. Boxed regions are identical or conserved residues. (b) 
Homology of the N-terminal amino acid sequence of GAP 31 with 
DNA topoisomerase II (DNA TOP), residues 660-699, from Droso- 
phi/a twlanogaster [I 11. Sequences are aligned to show maximum 
similarity. Solid lines indicate identical amino acids. Dotted lines indi- 
cate conserved amino acids. 
3.4. Cytotoxicity and toxicity 
The cytotoxicities of GAP 31, DAPs 30 and 32 were 
determined by their effects on cellular DNA and protein 
ceived similar injections of sterile PBS. The experiments 
were carried out using 4 mice in each group. The results 
are summarized in Table I. GAP 31 showed the least 
syntheses in uninfected H9 cells. The cells were grown 
in the presence and absence of the anti-I-W agent. Eight 
hours prior to harvest on day 4, the cells were pulse- 
labeled with [3FI]thymidine or [“HJleucine. Cellular in- 
corporation of [jW]thymidine or [3H]leucine into TCA- 
precipitable DNA or protein was measured. The results 
toxicity to intact mice, with an LDsO of 59-64 mg/kg. 
The LD,,s for DAP 32 and DAP 30 are 42-46 mg/kg 
and 12-16 mg/kg, respectively. In comparison, the 
LDs,s for trichosanthin and ricin are 5-7 mg/kg and 2-3 
/@kg. 
are shown in Fig. 4. From 0.32 to 32 nM, GAP 31 and 
DAP 32 caused no detectable ffect on cellular incorpo- 
ration of labeled thymidine or leucine, while p24 pro- 
duction and I-W-RT activity were inhibited more than 
90% (Fig. 3). At 32 nM however, T)AP 30 showed 25 
and 30% inhibition of the incorporation of 3H-labeled 
thymidine and leucine. At 320 r&I, or 1000 x IDso, still 
no inhibition of cellular DNA or protein synthesis was 
observed for GAP 31. At this concentration, DAP 32 
demonstrated 5 and 15% reduction on the incorpora- 
tion of 3H-lnbeled thymidine and leucine, respectively, 
and DAP 30 exhibited 40% inhibition of the incorpora- 
tion of these precursors. 
3.5. Ribosotne-inactivating activity 
Wibosome-inactivation was determined by the incor- 
poration of [3H]leucine into TCA-insoluble material as 
a function of the concentration of the anti-WV pro- 
teins. All three HIV inhibitors exhibit dose-dependent 
ribosome inactivation. As seen in Table I, ID,,, of 4.1, 
3.2 and 2.3 nM were obtained for GAP 31, DAP 30 and 
DAP 32, respectively. Thus these anti-HIV agents are 
also 
Cytotoxicity to uninfected cells in culture may be 
expressed as toxic dose 50 (TC,,), the dose at which 
cellular protein and DNA synthesis is inhibited by 50%. 
As summarized in Table I, the therapeutic index of GAP 
31, defined as the TD,, divided by the ID5(), exceeds 
single-chain ribosome-inactivating proteins 
(SCRIPS). They inhibit eukaryotic translation in cell- 
Table I 
The comparison of ribosomc-inactivating activity, anti-HIV activity. 
cytotoxicity and toxicity of various anti-HIV SCRIPS 
SCRIP Ribosome Anti-HIV cyto- Toxicity 
inactivation IDS,, (nM) toxicity 
10 000, using any of the three assays of antiviral activ- 
ity. The therapeutic indices for DAP 32 and DAP30 are 
in the range of 10 000 and 1000, respectively. 
The toxicity of GAP 31, DAP 30 and DAY 32 to 
‘i-I& LDso 
IDS, (tlM) Syncytkt P24 RT (nM) (my/kg) -- 
GAP 31 4.1 0,28 0.23 0.32 >3200 59-64 
DAP 30 3.4 0,76 0.85 0.88 910 12-16 
intact animals was studied on G- to S-weeks-old CFl 
mice. Filter-sterilized (0.2 pm) anti-HIV protein in PBS 
ws injected i,p. at doses of 0.1 1 1 .O, 10 and 100 mg per 
100 g body weight cvcry three days. Control animals re- 
DAP 32 243 0476 0.71 0.76 >3200 42-46 
-I-RI 3,7 0,34 0.37 0.46 340 5-Y 
nrc 2.3x 10-J 
_ 
TKI, trichosanthin; RIG. rich 
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free systems. However, they are not toxic to intact cells hibits the same level of anti-HIV activity and cytotox- 
because they do rmt enter intact normal cells. icity as DAP 30. 
3.6. N-Terminal amino acid sequence 
The N-terminal amino acid sequences of GAP 3 1, 
DAP 30 and DAP 32 are shown in Fig. 5. Comparison 
of the N-terminal sequence of these proteins with those 
of MAP 30 [I], lrichosanthin [3] and ricin A chain [4] 
reveals little homology. When considering identical resi- 
dues, GAP 31 shows only 0.2, 6.8, and 11% homology 
to ricin A chain, MAP 30, and trichosanthin, respec- 
tively. When both identical and conserved residues are 
considered, GAP 31 shows 22.7% homology to each of 
the three proteins. Similarly, DAP 30 and DAP 32 show 
8% homology for identical residues and 14% homology 
for conserved residues with MAP 30, trichosanthin, and 
ricin A chain. Most homology was found in aromatic 
(tyrosine and phenylalanine), hydrophobic, and hydro- 
xyl-containing amino acids. Furthermore, GAP 3 1 
shows little homology with DAP 30 and DAP 32 (7% 
identical and 12% conserved). Although the sequences 
of the two DAPs differ, 54.5% identity was found in the 
N-terminal 55 amino acid overlap. 
As seen in Fig. 6b, 48% homology was found between 
GAP 31 (residues l-40) and a DNA topoisomerase II, 
residues 660-699 [l 11. In the 40 amino acid overlap, 
40% identity is accountable. The significance of rhis 
homology between an anti-HIV protein and a DNA 
specific endonuclease is intriguing. Although these pro- 
teins have distinct specificities, they may share a com- 
mon strategy of action. Whether this is so warrants 
further study. 
4. DISCUSSION 
The anti-HIV activities in GAP 3 1: DAP 30 and DAP 
32 described here suggest that these compounds may be 
useful therapeutic agents in the treatment of HIV-l in- 
fection. Our results indicate that GAP 31 has the highest 
therapeutic index based on both TDSO/IDSO and LDSd 
IDSO ratios. The high anti-HIV activity and low cyto- 
toxicity of GAP 3 1 have also been independently confir- 
med. in human peripheral blood monocytes. These re- 
sults will be reported separately. 
lVIultiple forms of ribosome-inactivating proteins 
have been isolated from Gelonium multiJlorum and 
Dianthus caryophyllus [S,9]. However, no amino acid 
sequence data have been reported. Thus no comparison 
can be made with the sequence of our HIV inhibitors 
reported here. 
Comparison of the GAP 31, DAP 30 and DAP 32 
sequences to the EMBL data bank reveals some inter- 
esting findings. As shown in Fig. Ga, both DAP 30 and 
DAP 32 show significant homology to saporin-6 (SAP 
6), a SCRIP isolated from Saponaria offinalix [lo]. In 
the N-terminal 60 amino acid overlap, 65% identity was 
found between dianrhin 30 and saporin-6, and 48.3% 
identity was found between dianthin 32 and saporin-6. 
The finding of this homology, led us to assay SAP-6 for 
antiviral activity and cytotoxicity. As expected, it ex- 
While the anti-HIV activity of these compounds are 
similar, their cytotoxicities differ considerably. Little is 
known about the bases of such difference. Recently, we 
reported that two highly related anti-HIV proteins from 
trichosanthes displayed significant difference in cyto- 
toxicity [2]. Although their amino acid sequences at the 
N-terminal portion of 44 residues are highly homolo- 
gous, a stretch of five residues at position 12-16 namely 
-Eys-Eys-Lys-V~P-‘BT~P- for the non-toxic TAP 29 [2] and 
-Selp-Serp-~y~-‘-6ly-VaP- for the toxic trichosanthin differ 
completely [3,12-l 51. Examination of other non-toxic 
anti-HIV proteins, such as MAP 30 previously identi- 
fied [l] as well as GAP 31 and DAP 32 reported here 
as compared with relatively toxic DAP 30, SAP-6 [9] 
and ricin A chain [4], the absence of basic amino acids 
is noted in all toxic anti-HIV proteins. Table II indicates 
their difference, Interestingly, all of the non-toxic com- 
pounds have one or more Lys or Arg residues in this 
region; GAP 31 has a Lys at position 10, DAP 32 has 
an Arg at position 16, and MAP 30 has two Lys residues 
at positions 12 and 16. These Lys and Arg residues offer 
potential tryptic cleavage sites, These residues are ab- 
sent in the corresponding regions of the toxic SCRIPS, 
DAP 30, SAP-6, trichosanthin and ricin A chain. These 
results raise the possibility that the absence of basic 
residues in this unique region may play a role in the 
cytotoxicity of these anti-HIV proteins. 
The mechanism of anti-HIV action of these com- 
pounds remains to be elucidated. Our results indicate 
that they seem to exert their effects at multiples stages 
of the viral life cycle, affecting both viral infection and 
replication, The basis of their specificity may lie in the 
selective binding or uptake of these agents by viral in- 
fected cells; alternatively, they may be acting on the 
Table II 
Comparison of the N-terminal sequence IO-16 of some non-toxic and 
toxic anti-HIV proteins 
SCRIP Amino acid sequence IO-16 Cyto- Refcr- 
toxicity cnces 
TAP 29 -‘I’hr-Ser-Lye-Lys-Lye-Val-‘Syr- - 
MAP 30 -Thr-Xle-Lye-Thr-Tyr-Thr-Lys- - 1:; 
GAP 31 -Lye-Gly-Ala-Thr-Tyr-IJe-Thr- - 
D/U’ 32 -VaL-Ser-Pro-Ser-Ala-Asn-Arg- - 
DAP 30 -Asn-Pro-Ser-A1J-Ser-Gin-Tyr- + 
SAP-6 -Asn-Pro-Thr-Aln-Gly-Gin-‘Tyr- + [lOI 
TRI -Thr-Ser-Ser-Scr-Tyr-Gly-Val- ++ 
RIG A -Thr-VJ1-Cln-Ser-Tyr-TIIT-ASn.. + [3kY1 
Basic amino acids, lysinc (Lys) and argininc (kg), arc bold &cd. 
SAP-G, arrporin-6; TN, trichosanrhin; RIG A. ricirt A chain. 
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biochemical differences of the viral life cycle, or in- 
fected-cell metabolism as opposed to normal cell metab- 
olism. These mechanisms of action are not mutually 
exclusive, and some combination of them may account 
for the anti-HIV action of these compounds. Perhaps as 
striking as the specificity of action these agents display, 
is the observation that all of the plant anti-HIV proteins 
we have examined so far possess SCRIP activity as well. 
SGWIPs inactivate ribosomes by hydrolytically cleaving 
a glycosidic linkage between the adenine and the ribose 
at a highly specific site on the 2&S rRNA. The co-lo- 
calization of an anti-IIIV activity with this N-gly- 
cosidase activity suggests that these two activities may 
be related. Considering that HIV is a retrovieus and that 
SCRIPS are, in essence, highly specific RNA active 
reagents, raises the possibility that SCRIPS may exert 
their anti-I-IIV activity on the virus or viral specific 
metabolism directly. 
The extensive sequence homology between GAP 31 
and DNA topoisomerase II [Ill is worth noting. A 
stretch of 8 residues, ITYVNFLN of position 15-22 in 
GAP 3 1, is homologous to ITYADFIN at position 674- 
68 1 of DNA topoisomerase II. The complete homology 
over an octapeptide may imply a functional similarity 
between these proteins. GAP 31 is an anti-HIV SCRIP, 
capable of hydrolytic cleavage of a glycosidic linkage 
between the adenine and the ribose at A4324 on the 2% 
rRNA [16,17]. This function requires that it recognizes 
a specific base sequence in the rRNA. Topoisomerase 
II, on the other hand, is a specific endonuclease which 
makes double-stranded breaks at hypersensitive sites of 
DNA. This action is essential for the topological con- 
versions required during replication, transcription and 
chromatin assembly [IS’J. These recognition sites are 
commonly conserved and located in the loop regions of 
the nucleic acids [19]. Consequently, they may be the 
preferred targets for the integration of retroviruses as 
well [201. Studies on the structural-functional relation- 
Acknowledgement: S.L.H. acknowledges the support of her work by 
American EioSciences Inc. 
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